CoChat
Sign Up
Cited by 281

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

Koller, Erich, Vincent, Thomas M., Chappell, Alfred, De, Soma, Manoharan, Muthiah, Bennett, C. Frank·2011·Nucleic Acids Research
DOI 10.1093/nar/gkr089PMC PMC3113586
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkr089

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Ann. Rev. Pharmacol. Toxicol., 50, 259, 10.1146/annurev.pharmtox.010909.105654 · DOI
  2. Cerritelli, 2009, Ribonucelase H: the enzymes in eukaryotes, FEBS J., 276, 1494, 10.1111/j.1742-4658.2009.06908.x · DOI
  3. Wu, 2004, Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs, J. Biol. Chem., 279, 17181, 10.1074/jbc.M311683200 · DOI
  4. Dean, 1994, Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc. Natl Acad. Sci. USA, 91, 11762, 10.1073/pnas.91.24.11762 · DOI
  5. Butler, 2002, Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice, Diabetes, 1028, 10.2337/diabetes.51.4.1028 · DOI
  6. Chi, 2005, A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense to clusterin, in patients with localized prostate cancer prior to radical prostatectomy, J. Natl Cancer Inst., 97, 1287, 10.1093/jnci/dji252 · DOI
  7. Kastelein, 2006, Potent reduction of Apolipoprotein B and LDL cholesterol by an antisense inhibitor of Apolipoprotein B, Circulation, 114, 1729, 10.1161/CIRCULATIONAHA.105.606442 · DOI
  8. Sazani, 2002, Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat. Biotechnol., 20, 1228, 10.1038/nbt759 · DOI
  9. Vickers, 2006, Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide, J. Immunol., 176, 3652, 10.4049/jimmunol.176.6.3652 · DOI
  10. Geary, 2009, Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN, Biochem. Pharmacol., 78, 284, 10.1016/j.bcp.2009.04.013 · DOI
  11. Loke, 1989, Characterization of oligonucleotide transport into living cells, Proc. Natl Acad. Sci. USA, 86, 3474, 10.1073/pnas.86.10.3474 · DOI
  12. Crooke, 1995, In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides, J. Pharmacol. Exp. Ther., 275, 462, 10.1016/S0022-3565(25)12072-7 · DOI
  13. Krieg, 1993, Uptake and efficacy of phosphodiester and modified antisense oligonucleotides in primary cell cultures, Clin.Chem., 39, 710, 10.1093/clinchem/39.4.710 · DOI
  14. Iversen, 1992, Cellular Uptake and Subcellular Distribution of Phosphorothioate Oligonucleotides into Cultured Cells, Antisense Res. Dev., 2, 211, 10.1089/ard.1992.2.211 · DOI
  15. Bennett, 1992, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, Mol. Pharmacol., 41, 1023, 10.1016/S0026-895X(25)09229-6 · DOI
  16. Juliano, 2008, Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides, Nucleic Acids Res., 36, 4158, 10.1093/nar/gkn342 · DOI
  17. Stein, 2010, Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents, Nucleic Acids Res., 38, e3, 10.1093/nar/gkp841 · DOI · Paper page
  18. Nestle, 1994, Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes, J. Invest. Dermatol., 103, 569, 10.1111/1523-1747.ep12396876 · DOI
  19. Giachetti, 1996, Increased oligonucleotide permeability in keratinocytes of artificial skin correlates with differentiation and altered membrane function, J. Invest. Dermatol., 107, 256, 10.1111/1523-1747.ep12329755 · DOI
  20. Yu, 2001, Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice, J. Pharmacol. Exp. Ther., 296, 388, 10.1016/S0022-3565(24)38750-6 · DOI
  21. Dean, 1994, Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters, J. Biol. Chem., 269, 16416, 10.1016/S0021-9258(17)34023-1 · DOI
  22. Dean, 1997, Identification and characterization of second-generation antisense oligonucleotides, Antisense Nucleic Acid Drug Dev., 7, 229, 10.1089/oli.1.1997.7.229 · DOI
  23. Ruther, 1993, Inducible formation of liver tumors in transgenic mice, Oncogene, 8, 87
  24. Neufeld, 1997, Isolation of rat liver hepatocytes, Methods Mol. Biol., 75, 145
  25. McKay, 1999, Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression, J. Biol. Chem., 274, 1715, 10.1074/jbc.274.3.1715 · DOI
  26. Ravikumar, 2006, Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS), Bioorg. Med. Chem. Lett., 16, 2513, 10.1016/j.bmcl.2006.01.081 · DOI
  27. Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Annu. Rev. Pharmacol. Toxicol., 50, 259, 10.1146/annurev.pharmtox.010909.105654 · DOI
  28. Gaus, 1997, On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites, Anal. Chem., 69, 313, 10.1021/ac960557q · DOI
  29. Akinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat. Biotechnol., 26, 561, 10.1038/nbt1402 · DOI · Paper page
  30. Wilusz, 2008, 3′ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA, Cell, 135, 919, 10.1016/j.cell.2008.10.012 · DOI
  31. Donaldson, 1992, Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein, Nature, 360, 350, 10.1038/360350a0 · DOI
  32. Neufeld, 1996, Intracellular trafficking of cholesterol monitored with a cyclodextrin, J. Biol. Chem., 271, 21604, 10.1074/jbc.271.35.21604 · DOI
  33. Alberts, 1980, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent, Proc. Natl Acad. Sci. USA, 77, 3957, 10.1073/pnas.77.7.3957 · DOI
  34. Kolokoltsov, 2007, Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus, J. Virol., 81, 7786, 10.1128/JVI.02780-06 · DOI
  35. Schmid, 2007, Integrating molecular and network biology to decode endocytosis, Nature, 448, 883, 10.1038/nature06031 · DOI · Paper page
  36. Wieffer, 2009, SnapShot: endocytic trafficking, Cell, 137, 382, 10.1016/j.cell.2009.04.012 · DOI
  37. Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl Acad. Sci. USA, 105, 11915, 10.1073/pnas.0805434105 · DOI
  38. Bennett, 1992, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, Mol. Pharmacol., 41, 1023, 10.1016/S0026-895X(25)09229-6 · DOI
  39. Dean, 1994, Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc. Natl Acad. Sci. USA, 91, 11762, 10.1073/pnas.91.24.11762 · DOI
  40. Butler, 2002, Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice, Diabetes, 51, 1028, 10.2337/diabetes.51.4.1028 · DOI
  41. Wahlestedt, 1994, Antisense oligonucleotide strategies in neuropharmacology, Trends Pharmacol. Sci., 15, 42, 10.1016/0165-6147(94)90107-4 · DOI
  42. Zhang, 2000, Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis, Nat. Biotechnol., 18, 862, 10.1038/78475 · DOI
  43. Snyers, 2003, Human rhinovirus type 2 is internalized by clathrin-mediated endocytosis, J. Virol., 77, 5360, 10.1128/JVI.77.9.5360-5369.2003 · DOI
  44. Khan, 2010, Human rhinovirus 14 enters rhabdomyosarcoma cells expressing icam-1 by a clathrin-, caveolin-, and flotillin-independent pathway, J. Virol., 84, 3984, 10.1128/JVI.01693-09 · DOI
  45. Bayer, 2001, Inhibition of clathrin-dependent endocytosis has multiple effects on human rhinovirus serotype 2 cell entry, J. Biol. Chem., 276, 3952, 10.1074/jbc.M004722200 · DOI

Cited by

Sorted by citations

Metadata

Authors
Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F.
Venue
Nucleic Acids Research
Publisher
Oxford University Press (OUP)
Published
2011-02-23
Volume
39
Issue
11
Pages
4795-4807
ISSN
  • 1362-4962
  • 0305-1048
DOI
10.1093/nar/gkr089
PMC
PMC3113586
Cited by
281
References
2
Language
en
Licence
creativecommons.org/licenses/by-nc/2.5 (vor, 2050 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review